scholarly journals PTH-63 Eosinophilic oesophagitis – Our clinical experience with orodispersible tablet formulation budesonide (BOT)

Author(s):  
Michael Ding ◽  
Syazeddy Samani ◽  
Riad Alame ◽  
Sophie Houghton ◽  
Jenny Roylance ◽  
...  
Author(s):  
Gopinath E

Objective: The objective of the present work was to develop and evaluate a new, low-cost effective superdisintegrant from Musa acuminata fruit for tablet formulation.Methods: The study involved collection of M. acuminata fruit powdered and evaluated for physicochemical properties. Propranolol Hcl was used as a model drug for tablet formulation. Different concentrations of M. acuminatea powder were used as superdisintegrant, and orodispersible tablet is prepared and evaluated. In the present study, sodium starch glycolate was used as synthetic superdisintegrant for comparative study.Result: The powder was dark brownish and did not change throughout the study. The percentage porosity of powder was found to be 42.88% and angle of repose of was found to be 33.69°. The solubility study shows that the powders are sparingly soluble in water and disperse into individual particles. Total ash and acid insoluble ash values of powder were found to be 2.61 and 2.11% w/w, respectively. The average weight of tablets was ranged from 101.42 to 103.52 mg and averaged hardness was found to be 3.4 kg/cm2. Moreover, the tablets exhibited acceptable friability. Disintegration time of all formulations was found to be in the range of 22–80 s and wetting time was found to be 07–18 s.Conclusion: From the study, it was concluded that M. acuminatea powder in the range of 2–12% can be used as superdisintegrant in orodispersible tablet formulation and shall be preferred as having nutritive value as well as cost profit in the development of orodispersible tablet than synthetic polymer.


2010 ◽  
Vol 9 (2) ◽  
pp. 123
Author(s):  
H. Sperling ◽  
F. Debruyne ◽  
A. Boermans ◽  
M. Beneke ◽  
E. Ulbrich ◽  
...  

2020 ◽  
pp. flgastro-2019-101313
Author(s):  
Stephen Attwood ◽  
Jenny Epstein

Eosinophilic oesophagitis (EoE) is a disease identified just over 30 years ago. The main symptom is dysphagia. EoE is initially inflammatory and progresses to fibrosis. There are differences in clinical presentation between young children and adults. Diagnosis is by endoscopy and six biopsies at varying positions of the oesophageal lining. Blood tests are of no diagnostic value as the condition is mediated by IgG4 local mucosal pathology. Endoscopic signs are distinct from those of gastro-oesophageal reflux. Histological signs of EoE are >15 eosinophils/high-power field on a background of hyperplastic mucosa. Options of therapy include diet restriction, proton pump inhibitors therapy and topical steroids but there is a dearth of randomised control trials to define the optimum approach. The only licenced therapy for EoE is budesonide orodispersible tablet, a specific formulation for oesophageal topical steroid therapy. EoE is the most common cause of spontaneous perforation in the oesophagus. Stricture formation occurs in up to 10% and may require therapeutic dilatation.


2011 ◽  
Vol 31 (1) ◽  
pp. 27-41 ◽  
Author(s):  
Roland Heinig ◽  
Boris Weimann ◽  
Hartmut Dietrich ◽  
Michael-Friedrich Böttcher

2010 ◽  
Vol 7 (3) ◽  
pp. 325-325
Author(s):  
R. Heinig ◽  
B. Weimann ◽  
H. Dietrich ◽  
M.-F. Böttcher

2000 ◽  
Vol 64 (6) ◽  
pp. 440-444
Author(s):  
PC Lekic ◽  
RJ Schroth ◽  
O Odlum ◽  
J deVries ◽  
D Singer

Sign in / Sign up

Export Citation Format

Share Document